Trade
Dr Reddy's Laboratories share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹1,230.00(-1.26%)July 15, 2026 15:29:35 PM IST
- NSE
- BSE
- Vol : 1.76 M (NSE + BSE)Last 20 day avg : 2.73 M
Dr Reddy's Laboratories is trading -1.26% lower at Rs 1,230.00 as compared to its last closing price. Dr Reddy's Laboratories has been trading in the price range of 1,255.85 & 1,226.25. Dr Reddy's Laboratories has given -1.98% in this year & -8.00% in the last 5 days. Dr Reddy's Laboratories has TTM P/E ratio 24.90 as compared to the sector P/E of 25.20.There are 38 analysts who have initiated coverage on Dr Reddy's Laboratories. There are 5 analysts who have given it a strong buy rating & 11 analysts have given it a buy rating. 8 analysts have given the stock a sell rating.The company posted a net profit of 220.90 Crores in its last quarter.Listed peers of Dr Reddy's Laboratories include Lupin (1.07%), Torrent Pharmaceuticals (0.18%), Divi's Laboratories (1.38%).The Mutual Fund holding in Dr Reddy's Laboratories was at 13.19% in 31 Mar 2026. The MF holding has decreased from the last quarter. The FII holding in Dr Reddy's Laboratories was at 21.14% in 31 Mar 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 15, 2026, 11:14 AM UTC
- BetaLow volatility0.44Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.20The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.65Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.71The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values24.51Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation-10.16The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Dr Reddy's Laboratories News
Dr Reddy's Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Lupin | 2,495.80 | 1.07 | 1,14,116.68 | 28.78 | 5.59 | 0.57 | 11.80 |
| Torrent Pharmaceuticals | 4,980.00 | 0.18 | 1,68,598.41 | 67.32 | 17.1 | 0.83 | 17.62 |
| Divi's Laboratories | 7,284.60 | 1.38 | 1,93,383.24 | 78.61 | 11.52 | 0.46 | 0.01 |
| Cipla | 1,437.95 | -0.04 | 1,16,164.12 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | 1,954.15 | 0.72 | 4,68,855.00 | 36.24 | 5.77 | 0.92 | - |
Mutual Fund Ownership
View allDr Reddy's Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-22 | Quarterly Results |
| 2026-05-12 | Audited Results |
| 2026-01-21 | Quarterly Results |
| 2025-10-24 | Quarterly Results |
| 2025-05-09 | Audited Results, Dividend & Others |
About the company Dr Reddy's Laboratories
- IndustryBiotechnology & Drugs
- ISININE089A01031
- BSE Code500124
- NSE CodeDRREDDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Dr Reddy's Laboratories Share Price FAQs
Dr Reddy's Laboratories is trading at 1230.00 as on Wed Jul 15 2026 09:59:35. This is -1.26% lower as compared to its previous closing price of 1245.75.
The market capitalization of Dr Reddy's Laboratories is 102660.32 Cr as on Wed Jul 15 2026 09:59:35.
The average broker rating on Dr Reddy's Laboratories is Hold. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 11 analysts have given a buy rating
- 10 analysts have given a hold rating
- 8 analysts have given a sell rating
- 4 analysts have given a strong sell rating
The 52 wk high for Dr Reddy's Laboratories is 1414.40 whereas the 52 wk low is 1149.00
Dr Reddy's Laboratories can be analyzed on the following key metrics -
- TTM P/E: 24.90
- Sector P/E: 25.20
- Dividend Yield: 0.64%
- D/E ratio: 0.20
Dr Reddy's Laboratories reported a net profit of 4196.00 Cr in 2026.
The Mutual Fund Shareholding was 13.19% at the end of 31 Mar 2026.
Quick Links
EQUITY QUICK LINKS
Dr Reddy's Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.